Tech Company Financing Transactions
AVS Funding Round
AVS, based in Ann Arbor, secured $8.8 million from BioStar Capital and CUE Growth Partners.
Transaction Overview
Company Name
Announced On
4/4/2023
Transaction Type
Venture Equity
Amount
$8,800,000
Round
Series B
Investors
BioStar Capital (Lead Investor)
Proceeds Purpose
The company intends to use the funds to support clinical trials for its device for pulsatile intravascular lithotripsy (PIVL) in peripheral cases, while advancing preclinical work for an expanded indication in coronary cases.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
330 E. Liberty St Lower Level
Ann Arbor, MI 48104
USA
Ann Arbor, MI 48104
USA
Phone
Website
Email Address
Overview
AVS is an early-stage medical device company that is focused on safely and effectively treating severely calcified arterial disease. AVS is the first company to develop pulsatile intravascular lithotripsy (PIVL), a therapy that is delivered through a balloon-based platform called the Pulse IVL System. It is designed to be the only minimally invasive technology that gently shatters calcium and opens the artery using a single device.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mark Toland
Chief Technical Officer
Robert Chisena
Co-Founder
Hitinder Gurm
Browse more venture capital transactions:
Prev: 4/4/2023: Magnotherm venture capital transaction
Next: 4/4/2023: PureIMS venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on tech company VC transactions. VC investment data records reported here are sourced from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs